MapLight Therapeutics, Inc.
NASDAQ: MPLT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher A. Kroeger
- Employees
- 109
- Headquarters
- Redwood City, United States
- IPO year
- 2025
- Market cap
- $24.2M
- Website
- https://www.maplightrx.com
Loading MPLT…
Loading profile data…Frequently asked questions about MPLT
What does MapLight Therapeutics, Inc. (MPLT) do?
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced t...
Where does MPLT trade?
MapLight Therapeutics, Inc. (MPLT) trades on the NASDAQ Global Select.
What sector is MPLT in?
MapLight Therapeutics, Inc. (MPLT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MapLight Therapeutics, Inc.?
Christopher A. Kroeger is the chief executive officer of MapLight Therapeutics, Inc. (MPLT).
Where is MapLight Therapeutics, Inc. headquartered?
MapLight Therapeutics, Inc. is headquartered in United States.
Does MPLT pay a dividend?
MapLight Therapeutics, Inc. (MPLT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MPLT go public?
MapLight Therapeutics, Inc. (MPLT) completed its initial public offering in 2025.